Hyaluronidase Market Analysis

Product Segment Analysis

The recombinant segment in the market is expected to garner the largest share of 68.7% by the end of 2035. The segment’s exposure depends on the provision of a more versatile, consistent, and safer alternative to hyaluronidase, which has been readily derived from animal sources. According to an article published by the Drug Metabolism and Disposition in June 2023, the cytochrome P450 enzyme readily performs an effective xenobiotic biotransformation share, which CYPZD6, and it comprises an approximate 20% to 30% metabolism of common prescribed medications, thus making it suitable for the segment’s growth.

Distribution Channel Segment Analysis

The direct tender (institutional sales) segment in the hyaluronidase market is anticipated to account for the second-largest share during the forecast period. The segment’s upliftment is propelled by the involvement of manufacturers in negotiating supply contracts with institutional buyers, including private and public hospital networks, group purchasing organizations, and government health ministries. Besides, this model is effectively preferred for its cost-effectiveness and efficiency, since bulk processing through competitive tenders permits institutions to achieve generous volume discounts.

Application Segment Analysis

The drug delivery and dispersion segment in the market is projected to cater to the third-largest share by the end of the predicted duration. The segment’s growth is driven by its importance in breaking down hyaluronic acid, which is considered a substance in the extracellular matrix that tends to block drug dispersion and delivery. Besides, in November 2023, Acumen Pharmaceuticals, Inc. notified the international non-exclusive license agreement and collaboration with Halozyme Therapeutics Inc. to offer ENHANZE drug delivery accessibility, thereby denoting a positive impact on the overall segment.

Our in-depth analysis of the market includes the following segments: